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Abstract
Background: Understanding hepatic zonation is important both for liver physiology and pathology. There is
currently no effective systemic chemotherapy for human hepatocellular carcinoma (HCC) and its pathogenesis is of
special interest. Genomic and proteomic data of HCC cells in different culture models, coupled to pathway-based
analysis, can help identify HCC-related gene and pathway dysfunctions.
Results: We identified zonation-related expression profiles contributing to selective phenotypes of HCC, by
integrating relevant experimental observations through gene set enrichment analysis (GSEA). Analysis was based on
gene and protein expression data measured on a human HCC cell line (HepG2/C3A) in two culture conditions:
dynamic microfluidic biochips and static Petri dishes. Metabolic activity (HCC-related cytochromes P450) and
genetic information processing were dominant in the dynamic cultures, in contrast to kinase signaling and cancer-
specific profiles in static cultures. That, together with analysis of the published literature, leads us to propose that
biochips culture conditions induce a periportal-like hepatocyte phenotype while standard plates cultures are more
representative of a perivenous-like phenotype. Both proteomic data and GSEA results further reveal distinct
ubiquitin-mediated protein regulation in the two culture conditions.
Conclusions: Pathways analysis, using gene and protein expression data from two cell culture models, confirmed
specific human HCC phenotypes with regard to CYPs and kinases, and revealed a zonation-related pattern of
expression. Ubiquitin-mediated regulation mechanism gives plausible explanations of our findings. Altogether, our
results suggest that strategies aimed at inhibiting activated kinases and signaling pathways may lead to enhanced
metabolism-mediated drug resistance of treated tumors. If that were the case, mitigating inhibition or targeting
inactive forms of kinases would be an alternative.
Keywords: hepatocellular carcinoma, hepatic zonation, ubiquitination system, gene sets analysis, Petri plates, PDMS
microfluidic biochips
Background
The functional unit of the liver, the lobule, is roughly
cylindrical, with branches of the hepatic artery and por-
tal vein together with bile ducts at its periphery, and a
central vein branch in the middle. Such a structure
allows a natural distinction between upstream “peripor-
tal” and downstream “perivenous” hepatocytes, and con-
stitutes the basis for “liver zonation”. It is generally
accepted that the homeostatic function of the liver
depends on the functional complementation of those
two zones [1-3]. Different, or even opposite, metabolic
functions are often found between periportal and perive-
nous hepatocytes [4,5]. That heterogeneity is important
for understanding of various aspects of liver function
and pathology [2], and is widely studied [5-7]. However,
little attention has been paid so far to zonation-like
alterations associated with human hepatocellular carci-
noma (HCC), which is one of the most frequent visceral
neoplasms worldwide [8].
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Accumulating evidence indicates that WNT/b-catenin
signaling plays a central role in the multi-level regula-
tion of zonal gene expression in the liver [5]. It is also
implicated in several critical pathways responsible for
initiating and maintaining dysregulated cell proliferation
in HCC [9]. A key factor in the WNT/b-catenin signal
transduction pathway is the success or failure of protea-
somal degradation of the cytosol b-catenin. Migration of
accumulated b-catenin to the nucleus subsequently
induces the synthesis of several tumor promoters. In
normal physiological conditions, b-catenin activation is
restricted to perivenous hepatocytes [10,11], where it
both induces “perivenous” gene expression and inhibits
“periportal” gene expression [10]. Genetic therapy of
HCC faces severe challenges, since HCC involves
genetic alterations of multiple genes in several regula-
tory pathways simultaneously [8]. Understanding the
relationships between the zonation of these pathways in
the liver may deepen our views on the pathogenesis of
HCC, its proliferation or maintenance.
The ubiquitin-proteasome system, a highly conserved
eukaryotic system for cellular protein degradation, is
important for cancer cells to block apoptosis or other
normal cellular processes [9]. The levels of proteins in
the nucleus, cytoplasm, endoplasmic reticulum lumen,
and in membranes, are all kept in check by the ubiquiti-
nation enzymes and the proteasome [12]. A variety of
healthy or diseased cell functions are affected by this
regulatory mechanism. The corresponding signaling cas-
cade includes the ubiquitin-activating enzyme E1, ubi-
quitin-conjugating enzymes E2 and a highly diverse
class of ubiquitin ligases E3. The wide variety of E3
ligases, mainly including the RING-, SCF-, HECT- and
U-box-types, target a tremendous number of proteins
for ubiquitination. For example, c-Cbl E3 ligase ubiquiti-
nates several receptor protein-tyrosine kinases [13,14].
Alterations in protein ubiquitination, such as modified
affinity of a signaling receptor for E3 enzymes after
phosphorylation of its intracellular domain, lead to dys-
regulated signaling, promotion of cancer cells’ growth
and their withstanding of anti-proliferative and cell
death stimuli [14,15].
With the increasing availability of transcriptomic and
proteomic data, pathway analysis has become a signifi-
cant avenue to uncover the structure of functional/regu-
latory networks in tumoral or normal tissues. Pathway-
based analyses are usually based on an assessment of
correlations in genes or proteins expressions. Various
algorithms, such as gene set enrichment analysis (GSEA)
[16,17] and structural information based pathway analy-
sis [18], have been developed to identify biologically
relevant pathways. Those methods may take advantage
of information previously gathered in databases such as
KEGG (Kyoto Encyclopedia of Genes and Genomes,
http://www.genome.jp/kegg/) or BioCarta to improve
statistical power. A pathway approach has been able, for
example, to identify a coordinated decrease in the
expression of functional signals in human diabetes [16].
Meanwhile, technological advances in liver tissue engi-
neering and biomechanics allow in vitro studies with
much tighter control of extraneous conditions. Numer-
ous in vitro hepatocyte models have been proposed [19].
Hepatocyte cultures are one of the most successful in
vitro systems, since liver-specific functions and response
to stressors can be maintained with appropriate culture
conditions [7]. The major problems can be limited viabi-
lity, associated with the loss of phase I and phase II bio-
transformation capacity [20]. “Biochips” grow cells in a
microfluidic network, allowing a better control of
dynamic cultures by continuous feeding of nutrients to
cells and waste removal [21,22]. Previous transcriptomic
analyses of hepatocyte function in dynamic biochips
showed that phase I and phase II enzymes were signifi-
cantly up-regulated and xenobiotic metabolism main-
tained [23].
In this study, we carried out an extensive GSEA path-
way analysis of gene and protein expression data from
HCC cells grown in either microfluidic biochips (μFB)
or Petri dishes (PD), representing dynamic and static
micro-environments, respectively. On the basis of these
analyses, we investigated the relationship between acti-
vated pathways, experimental RT-qPCR data, and daily
hepatocytes’ metabolic activities [23], in the framework
of hepatic zonation. Finally, the distinct effects of
matched protein expression data in the two groups led
us to investigate the role of ubiquitination in the onset
of oncogenic properties.
Results
Different categories of pathways are activated in μFB and
PD
We performed GSEA [16,17] of gene transcription and
protein expression data obtained in human HCC cell
lines cultured in μFB and PD. Gene expression data
were used alone or in combination with matched pro-
tein expression data. The pathways definitions used
were those of the KEGG database. Table 1 categorizes
the gene sets differentially expressed in the μFB and
PD groups with a false discovery rate (FDR) ≤ 0.25
(they mostly have a nominal p value < 0.05). The num-
ber of pathways found and their specificities were quite
different between the two culture conditions. A pro-
nounced metabolism-pathways profile was found in
μFB, while a signaling-pathways profile (referring to
environmental information processing) dominated in
PD (see Additional file 1, Table S1 and Additional file
2, Table S2 for a detailed list of the pathways). That
result is supported by the observation that, compared
Cheng et al. BMC Genomics 2012, 13:54
http://www.biomedcentral.com/1471-2164/13/54
Page 2 of 10
to other KEGG pathway categories, signaling and regu-
lar metabolic pathways have a general tendency to lose
their gene expression coherence in tumor cells [24].
Typical liver-function-specific pathways (e.g., metabo-
lism of xenobiotics by cytochrome P450 and primary
bile acid biosynthesis) and cancer-related pathways (e.
g., MAPK signaling) were significantly activated in the
μFB and PD groups, respectively. The result on meta-
bolic pathways in μFB is supported by [23], and indi-
cates that μFB cultures represent a 3D culture
condition yielding metabolically competent cells, closer
in phenotype to primary human hepatocytes [22,25].
Among the metabolic pathways activated in μFB, only
one out of 29 concerned energy metabolism (i.e., oxi-
dative phosphorylation), which has been shown to be
mostly periportal [26] (Additional file 1, Table S1).
Only nitrogen energy metabolism was activated in PD
(Additional file 2, Table S2). Genetic information pro-
cessing pathways, which are highly correlated with
genomic alterations in HCC [8], were the second most
activated in μFB while the corresponding information
was lost in PD (Table 1). Previous experiments in mice
liver lobules suggest that the perivenous genetic pro-
gram is switched off, and the periportal program
switched on, by a WNT inhibitor or by lowered
expression of b-catenin [26]. Using the same gene
expression data, there were 11 pathways with an FDR
≈ 0 in μFB (data not shown) and only one in PD:
“maturity onset of diabetes of the young”, a monogenic
form of type 2 diabetes [27], which is in agreement
with our cell model.
Results with and without protein data included were
not very different, due to the much lower number of
identified relevant proteins. However, close examination
showed that the effects of protein data inclusion were
quite opposite in the μFB and PD groups: In μFB, the
total number of pathways was reduced, although new
pathways such as RIG-I-like receptor signaling were
activated; In PD, an increased number of pathways were
identified (Additional file 1, Table S1 and Additional file
2, Table S2).
HCC-related CYPs and kinases represent the cancer
phenotypes in μFB and PD, respectively
We proceeded to assess whether one of the above
identified pathways offered a clear separation of the
HCC phenotypes in μFB and PD. That is especially
useful for manually curated gene sets like KEGG path-
ways, which may represent amalgamated processes
[17]. GSEA was used to examine, at the gene level, the
leading-edge pathways identified above. Table 2 pre-
sents the top genes participating to at least four path-
ways identified using both gene and protein expression
data (the detail of the genes and connected pathways
in μFB using gene expression data are shown in Addi-
tional file 3, Figure S1). Eleven and 16 genes are
included in the μFB and PD, respectively. Overall,
there is notably more gene sharing in the top 22 PD
pathways than in the top 40 μFB pathways, indicating
a high density of pathway cross talk in PD, consistent
with the least cohesive property of signaling pathways
[24]. Yet, in both groups, many genes belong to a com-
mon gene family. In μFB cultures, four (one CYP1A
and three CYP3A) out of 11 genes are the members of
cytochrome P450 superfamily. HCC has effects on the
expression of CYP1A and CYP3A genes [28,29]. In
particular, CYP3A4 shows a notable increase in gene
copies and mRNA transcripts in HCC cell lines from
eight ethnically diverse human populations [30]. In PD
cultures, twelve of the genes found (BRAF, MAPK3,
MYC, TGFB2, EGFR, CDC42, PDGFRA, CREBBP,
PDGFB, RAP1A, PAK1, PRKCG), out of 16, are mani-
fested in hepato-carcinogenesis [9]. They belong to
kinases and proteins having kinase activities, growth
factors and transcription factors playing critical roles
in HCC, and several of them are targets of drug cur-
rently tried for HCC treatment.
Periportal- and perivenous-like pathways characterize μFB
and PD, respectively
Although specific liver functions and HCC signals are
more or less expressed in the two groups, the overall
μFB and PD cellular phenotypes are quite different. Pre-
vious studies indicate that the loss or gain of b-catenin
signaling has important consequences; In the former
case, liver cells acquire a periportal-like phenotype [26].
We thus postulated that the pathways patterns observed
in the μFB and PD groups could be interpreted as the
result of loss or over-activation of the b-catenin path-
way, respectively. That was hinted at by the elevated
expression levels of periportal-like and perivenous-like
markers in the above GSEA results, but also in
Table 1 Statistical summary by categories of the KEGG
gene pathways identified by GSEA (FDR ≤ 0.25), on the
basis of differential gene and protein expressions
between μFB and PD cultured HepG2/C3A cells
Pathway category μFB cultures PD cultures
Metabolism 29/25 a 1/2
Genetic Information Processing 8/7 0/0
Environmental Information Processing 1/1 6/7
Cellular Processes 3/3 1/1
Organismal Systems 2/2 5/5
Human Diseases 1/2 4/7
Total 44/40 17/22
a results using gene expression data only/results using gene and protein
expression data.
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previously published RT-qPCR and metabolic activity
data [23].
Under normal conditions, the expression of cyto-
chromes P450 is mostly restricted to perivenous hepato-
cytes and under b-catenin regulation. The hypothesis
that b-catenin signaling is localized in the perivenous
area has been well described [5,10]. Evidence has been
recently provided that, in b-catenin knockout mice,
CYP1A and CYP3A expression is strongly altered [5,31]:
High CYP3A mRNA and protein levels are observed in
periportal hepatocytes, while CYP1A induction by AhR
agonists occurred uniformly in all hepatocytes. In rat
liver, low doses of b-naphtoflavone lead to CYP1A1
induction in periportal hepatocytes [32,33]. On the
other hand, CYP3A zonation is completely lost in
human HCC [34].
In the above GSEA analyses, only the CYP1A and 3A
families (among the 60 CYP isoforms) were found in the
top-ranking pathways for μFB cultures (Table 2 and
Additional file 3, Figure S1). Similarly, RT-qPCR has
shown up-regulation of CYP1A1, 1A2, 3A4, 3A5 and
3A7, with a slight induction of AhR transcription (for
CYP1A) and PXR transcription (for CYP3A) in μFB cul-
tures, compared to PD cultures [23].
To visualize b-catenin signaling expression in PD cul-
tures, the KEGG WNT signaling pathway was drawn by
Paintomics [35] on the basis of the PD gene expression
data (Additional file 4, Figure S2). Over-expressed genes
dominate the painted WNT signaling pathway, with
dense connections between WNT signaling and the
pathways governing focal adhesion, MAPK, TGF-b and
calcium signaling pathways, all activated in PD cultures.
Other relevant expressions in PD cultures are the nitro-
gen metabolism pathway, controlled by b-catenin [10],
and the EGFR gene, which enhances b-catenin tran-
scriptional activity [36]. Furthermore, five genes, each of
which participates in the overlapping four pathways in
PD cultures, are involved in the WNT signaling pathway
(CREBBP, MYC, PRKCG, PPP3CC and PPP3R2) (Figure
1). These genes might constitute the specific induction
of WNT signaling in HepG2/C3A cells (originating
from an adolescent’s liver) although MYC is normally
not induced by b-catenin signaling in the adult liver
[26]. The absence of CYPs in HepG2/C3A PD cultures
is consistent with the overall repressive effect of Ras-
Raf-MAPK signaling on expression of CYP enzymes
[37].
Differences in glutamine-related ammonia detoxification
between μFB and PD cultures also maps to the spatial
heterogeneity of hepatocytes in vivo. Periportal glutami-
nase and perivenous glutamine synthetase genes are
respectively negatively and positively controlled by b-
catenin [26] (Figure 2A). Therefore, the net glutamine
balance across the liver, involving periportal consump-
tion and perivenous glutamine synthesis, can be either
positive, negative or zero, depending on experimental
conditions [38]. Glutamine consumption was found to
be higher in μFB than in PD cultures, especially after 48
h [23] (Figure 2B). Dynamic flow conditions in micro-
fluidic bioreactors lead to increased glutamine consump-
tion and ammonia production, compared to static
bioreactor conditions or Petri dishes [39]. Glutaminase
activity might therefore be more active in μFB as it is in
the periportal area, while glutamine synthetase activity
should dominate in PD, like in perivenous hepatocytes.
Taken together, those results suggest that the periportal-
and perivenous-like pathways are differentially activated in
dynamic μFB and static PD, respectively (Figure 3).
Distinct ubiquitin-mediated regulations in μFB and PD
cultured cancer cells
As mentioned above, including protein expression data
in the initial GSEA had distinct effects on pathway
inference for μFB and PD cultures (Table 1, Additional
file 1, Table S1 and Additional file 2, Table S2). That
suggests that the coordination of gene and protein
expressions is somewhat different in the two culture
types. Post-transcriptional mechanisms, such as protein
degradation, are among the possible explanations for
that observation. We thus explored a possible role of
ubiquitination in leading to the observed cell phenotypes
(Additional file 5, Table S3) and GSEA results.
Table 2 Genes a present in at least four of the pathways analyzed in Table 1, using gene and protein expression data
together
Genes Number of
μFB cultures PD cultures pathways
CYP3A43 CYP3A4 CYP3A7 6
POLD3 POLD2
ALDH3A2 ALDH2 BRAF 5
POLE2 POLE3 RPA2 MAPK3 MYC PPP3CC IL5 TGFB2
CYP1A1 EGFR CACNA1C CDC42 PDGFRA CREBBP 4
PDGFB RAP1A PAK1 PRKCG PPP3RR2
a Genes in bold font code for HCC-related CYPs in the μFB group, and for kinases (or protein having kinase activity) in the PD group.
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In μFB cultures, there appears to be a loss of b-cate-
nin pathway activity, which might correlate to the acti-
vated “proteasomal” (Additional file 1, Table S1)
digestion of b-catenin. That degradation has been
shown to be dependent on the shuttling of APC [40]
(Figure 4). The loss of b-catenin regulation might favor
the activation of genetic pathways over signaling path-
ways. Almost 50% of the top genes differentially
expressed in μFB cultures (POLD, POLE and RPA
genes) (Table 2) are involved in chromosomal DNA
replication. Proteomic analysis showed an elevated pro-
tein expression of DNA repair (including MCM7,
RBBP4, NCL and PCNA) in μFB cultures. In addition,
increasing evidence links proteasome function with cha-
perones [12]. An observed over-expression of
HSP90AA1 and AB1 proteins might be in response to
the degradation of CYP2E1 [41]. GSEA excluded
CYP2E1 from the list of enriched genes in the “metabo-
lism of xenobiotics by cytochrome P450” and “drug
metabolism cytochrome P450” pathways (data not
shown). That result is in accordance with the HCC
database [42] which shows that almost half of the speci-
mens of CYP2E1 are either up- or down-regulated in a
ratio of 10 to 339. Overall, in μFB cultured HCC cells, a
high degree of genetic instability seems to facilitate the
inactivation of normal and tumor suppressor proteins as
well as the activation of HCC-related proteins like
CYP1A and CYP3A.
In PD cultures, E3 ubiquitin ligases RNF2 and RNF20,
cathepsins B, C and D, all of which are involved in the
ubiquitination system, had significantly elevated expres-
sion (Additional file 5, Table S3). They may play a
major role in directing the signaling proteins singled out
by GSEA to ubiquitination and lysosomal degradation
(Figure 4 and Table 2). For instance, it has been clearly
shown that the RING finger ligase can be recruited by
EGFR for subsequent routing to lysosomal degradation
[43]. Yet, in most cases, ubiquitinated EGFR activates
the internalization and is not targeted by the protea-
some [12]. The altered proteolytic machinery may imply
an ubiquitin modulation of EGFR, which could be asso-
ciated with distinct stages in the transition to the active
kinase forms of EGFR [44,45]. That may serve as a tem-
poral/spatial control of EGF signaling, which finely regu-
lates pathways related to survival, proliferation and
angiogenesis. Similarly, the receptor tyrosine kinase
Figure 1 A joint subset of five genes, each of which participates in the overlapping four pathways in the PD group, constitutes the
WNT signaling sub-pathway (CREBBP, MYC, PRKCG, PPP3CC and PPP3R2). These genes might constitute the specific induction of WNT
signaling in HepG2/C3A cells (originating from an adolescent’s liver).
Figure 2 Zonated glutamine cycling in the liver. (A) b-catenin exerts either negative or positive control on glutaminase and glutamine
synthetase, respectively. Periportal glutamine consumption is catalyzed by glutaminase. Perivenous glutamine synthesis is catalyzed by glutamine
synthetase. (B) Daily glutamine consumption is higher in μFB cultures than in PD cultures. Data are expressed as mean ± SD (N = 6).
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Figure 3 Schematic representation of the activated signals corresponding to periportal-like HCC (μFB cultures) and perivenous-like
HCC (PD cultures) as the result of loss or over-activation of b-catenin, respectively. Genetic pathways are significantly induced under loss
of b-catenin, leading to periportal-like phenotype (with production of energy by oxidative phosphorylation) in μFB hepatocytes. b-catenin-
dependent signals are significantly enriched in the perivenous-like hepatocytes of PD cultures.
Figure 4 Distinct ubiquitination-mediated proteins regulation in the μFB (Biochips) and PD (Petri) cultured HCC cells. (A) regulation
through genetic alteration coupling with proteasomal degradation and apoptosis. (B) regulation through signaling alteration by signaling
proteins ubiquitination.
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PDGFRA, together with its ligand, participates to these
pathways and is a substrate of c-Cbl E3 ubiquitin ligase
[14,46]. The TGF-b ligand itself plays an important role
in cancer progression by functioning both as an anti-
proliferative factor and as a tumor promoter [47], and
the ubiquitin-proteasome system is known to regulate
the core intracellular signaling cascade SMAD proteins
[9,12,47]. Therefore, in contrast to the μFB culture phe-
notype which may result from genetic alterations, the
PD cultured HCC cell phenotype could be influenced by
an altered ubiquitination of signaling proteins.
Discussion
The emerging consensus on hepatic zonation is that it
spatially separates pathways to avoid interference and
energy wastage [48]. This notion is compatible with our
proposed parallel between zonation profiles and culture
types: Upstream hepatocytes, as in biochips cultures,
exhibit broad metabolic and genetic profiles; Down-
stream hepatocytes, as in plates, display mainly signaling
and disease processes.
Previous studies have pointed to several limitations of
HepG2 hepatocytes: A repression of various CYP iso-
forms by the EGF/Ras/MAPK signaling transduction
pathway [37]; The development of a periportal genetic
program, allowed by inhibition of WNT signaling [10];
The absence of a urea cycle, leading to ammonia detoxi-
fication only via glutamine synthesis [49]. The first two
limitations are clearly culture-type dependent, as shown
by our analysis of μFB and PD culture conditions. As
for the third limitation, our study indicates that favoring
a periportal-like phenotype in μFB cultured hepatocytes
might improve urea synthesis in HepG2 cells. We assert
that the causes of these limitations are linked to the b-
catenin pathway. That, however, remains to be experi-
mentally confirmed, because other regulatory pathways
might be involved as well. It would be especially inter-
esting, for example, to study wild-type CTNNB1 hepa-
toma cells which express b-catenin and metabolic
enzymes at levels even closer to the in vivo situation.
It is interesting to note that HCC-related CYPs were
activated in μFB cultures, where a deficit in signaling
pathways was observed. On the other hand, protein
kinases were activated in PD cultures, with a serious
deficit in metabolic pathways. It seems reasonable to
assume that both pathway categories need to be
balanced, and that imbalance leads to homeostasis
abnormalities. That is important because much efforts
are devoted to developing kinases and signaling path-
ways inhibitors for therapeutic intervention. The results
presented here indicate that in such conditions, cancer
cells may spontaneously develop metabolism-mediated
resistance. In that case, it might be worth to mitigate
inhibition of the active form of kinases, or to target
inactive kinase conformations (e.g., PDGFR and BRAF
inhibitors [50]). The initial stage of inactivation of a
typical cancer-related kinase (PKB/AKT) has been
recently described [45].
Protein phosphorylation and ubiquitination go hand in
hand in the regulation of many cellular processes, and
phosphorylation typically precedes ubiquitination [12]. It
is commonly thought that the loss of apoptosis is
required for carcinogenesis, and that cancer cells aim to
develop survival and growth. However, different envir-
onmental changes, which can be related to personalized
medicine, can significantly modulate the cells responses
such as the genetic alteration coupled with proteasomal
degradation and apoptosis in μFB cultured HCC cells,
and signaling alteration in PD cultures. Moreover, the
fact that ubiquitinated EGFR is in most cases not tar-
geted to the proteasome may indicate that signaling
pathways remain functional despite the ubiquitination of
their proteins, but this remains to be investigated.
Conclusions
This paper describes links between b-catenin controlled
hepatic zonation and the phenotype of HepG2 cells
grown in dynamic μFB cultures or static PD conditions,
on the basis of gene and protein expression data.
CYP1A/3A and kinases are representative of the cancer
phenotypes in μFB and PD, respectively. Plausible ubi-
quitin-mediated regulation mechanisms are proposed
for b-catenin degradation in μFB, and ubiquitin altera-
tion of signaling proteins in PD.
Methods
Hepatocyte cell line
The human HCC cell line HepG2/C3A used was from
the American Type Culture Collection (ATCC), number
CRL-10741. HepG2/C3A was derived from the liver tis-
sue of a fifteen year old male. C3A is a clonal derivative
of HepG2 that was selected for strong contact inhibition
of growth, high albumin production, high production of
alpha fetoprotein (AFP) and ability to grow in glucose
deficient medium http://www.atcc.org.
Cell culture conditions: biochips and Petri
The microfluidic biochip fabrication, based on polydi-
methylsiloxane (PDMS), is detailed in [23,39].
The biochips had a volume estimated at 40 μL and the
total surface available to cell growth was about 2 cm2.
The inner surface of the biochips was coated with 10
μg/mL fibronectin for 40 min. The cells were inoculated
in the biochip at the density of 0.25·106 cells/cm2 in 0.5
ml medium and then kept at rest 24 h in a 5% CO2
incubator at 37°C. The culture medium was perfused at
a 10 uL/min flow for 72 h and altogether 96 h for cells
in the cultures.
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In Petri cultures, the cells were seeded at the same
density as in biochips, in 12-well culture plates, contain-
ing 2 mL medium covered initially with 0.5 mL PDMS
and coated with fibronectin as in the biochips. Cells
were cultivated for a total of 96 h including the first 24
h of adhesion phase.
Transcriptional and protein level datasets
The gene expression data were generated using Affyme-
trix Genechip microarrays. The relevant technique is
detailed in [23]. The GEO access of the data is
GSE27420. The protein level data were obtained via 2D
DIGE technique and are detailed in Additional file 5,
Table S3.
There were 21380 differentially expressed genes in
each of the triplicates biochips and Petri experiments.
The average coefficient of variation (CV) of the triplicate
gene expression measurements was 2.6% in biochips and
2.4% in Petri plates; The 95th percentile of the CVs of
all genes was 6.6% in biochips and 6.3% in Petri. The
variability across replicates was therefore fairly low and
for the subsequent analyses we used the mean expres-
sion values of the triplicates for each gene. Only 101
proteins were identified. The ratio of biochip to Petri
expression was used for biochips and the value “1”
assigned to all the Petri protein expressions.
Gene set enrichment analysis (GSEA)
GSEA determines whether the members of a given gene
set are enriched among the most differentially expressed
genes between two classes. Calculation of the enrich-
ment score ES is the key component of GSEA, which is
given by




















where a gene set S has NH genes which forms the
ranked order L = (g1, ..., gN) according to the correlation,
r(gi) = rj of their expression profiles with a phenotype C,
and the ES is the maximum deviation from zero of Phit -
Pmiss, representing the fraction of genes in S weighted by
their correlation minus the fraction of genes not in S.
The false discovery rate (FDR) was used for significance
testing. GSEA is implemented as a software tool; for
details see [16,17]. We ran GSEA using the unfiltered
data, as recommended.
WNT signaling pathway visualization. Paintomics [35]
for KEGG pathway visualization was used to display the
WNT signaling pathway; Pathway enrichment measure
was based on the Fisher’s exact test. The gene expres-
sion data from PD were first log-transformed and nor-
malized by subtraction of the mean value of all genes.
Genes with values higher than the mean value were
colored in red and in blue otherwise, while the intensity
was proportional to the differentially expressed level.
Additional material
Additional file 1: Table S1: Specific pathways and involved gene
counts in the biochips group using two expression data sets (FDR ≤
0.25). The results are from GSEA using KEGG database.
Additional file 2: Table S2: Specific pathways and involved gene
counts in the Petri group using two expression data sets (FDR ≤
0.25). The results are from GSEA using KEGG database.
Additional file 3: Figure S1: The detailed top common genes of
POLD(A), CYP3A(B), ALDH and EHHADH(C) together with their
connected pathways in the biochips group using gene expression
data.
Additional file 4: Figure S2: Painted WNT signaling pathway based
on the Petri gene expression data using Paintomics. Genes with
values higher than the mean value of all gene expressions are colored in
red and otherwise in blue, while the intensity is proportional to the
differentially expressed level. The image shows the link-outs to other
pathways as well.
Additional file 5: Table S3: Proteins differentially expressed by the
biochips versus the Petri via 2D DIGE technique.
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